Paper Details

  1. Home
  2. Paper Details

Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.

Author: CasteloEdward, CowenJennifer, LevittJennifer, McCrackenJames T, McGoughJames J, SayerGregory R, SturmAlexandra

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Guanfacine immediate-release (GUAN-IR), dexmethylphenidate extended-release (DMPH), and their combination (COMB) were well tolerated and safe in youth with attention-deficit/hyperactivity disorder. GUAN-IR reduced heart rate, while DMPH increased heart rate. COMB had intermediate effects. Long-term treatment with GUAN-IR and DMPH returned cardiovascular parameters to baseline.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: This study examines cardiovascular (CV) effects of guanfacine immediate-release (GUAN-IR), dexmethylphenidate extended-release (DMPH), and their combination (COMB) during acute and long-term treatment of youth with attention-deficit/hyperactivity disorder. METHODS: Two hundred seven par...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178010/

データ提供：米国国立医学図書館（NLM）

Navigating the Cardiovascular Effects of ADHD Medications

This research explores the cardiovascular effects of medications commonly used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). The study, like a camel caravan setting out on a long journey, aimed to assess the safety and effectiveness of guanfacine, dexmethylphenidate, and their combination in treating ADHD. The researchers meticulously tracked cardiovascular parameters, such as heart rate and blood pressure, during both the acute and long-term phases of treatment, ensuring a comprehensive understanding of the medications' effects on the cardiovascular system.

A Steady Path Through the Desert of ADHD

The study found that guanfacine was associated with decreases in heart rate and blood pressure, while dexmethylphenidate led to increases in these parameters. The combination therapy, however, resulted in changes that fell between the two monotherapies. The researchers also noted that the cardiovascular effects of guanfacine and dexmethylphenidate tended to return to baseline levels with sustained therapy, suggesting that the medications may be safe for long-term use.

The Importance of Careful Monitoring and Individualized Treatment

This study highlights the need for careful monitoring of cardiovascular parameters when treating ADHD with these medications. Individualized treatment plans may be necessary to minimize potential risks and maximize benefits. Just as a camel needs to adapt its pace to the terrain, patients with ADHD may require tailored treatment plans to navigate the challenges of their condition.

Dr.Camel's Conclusion

This study provides valuable insights into the cardiovascular effects of medications used to treat ADHD, like a camel navigating a desert landscape with different terrains. It's important to consider the potential cardiovascular impacts of these medications and work closely with a healthcare professional to find the safest and most effective treatment plan.

Date :
  1. Date Completed 2017-12-13
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

27483130

DOI: Digital Object Identifier

PMC5178010

Related Literature

Article Analysis
・Effects of dexmethylphenidate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.